Trojan, Lutz

[["dc.bibliographiccitation.firstpage","3010"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Delonge, Laura M."],["dc.contributor.author","Haack, Anna-Maria"],["dc.contributor.author","Shuch, Brian"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2021-04-14T08:31:08Z"],["dc.date.available","2021-04-14T08:31:08Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12103010"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83497"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","574"],["dc.bibliographiccitation.journal","SpringerPlus"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Jarry, Hubertus"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:33:49Z"],["dc.date.available","2018-11-07T09:33:49Z"],["dc.date.issued","2014"],["dc.description.abstract","Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC) involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless, limitations to an enduring effectiveness of new drugs are anticipated in resistance mechanisms occurring under such treatments. In this study we used CRPC cell models VCaP and LNCaP as well as AR-negative PC-3- and non-neoplastic epithelial BPH-1-cells treated with 5, 10 or 25 mu mol/L abiraterone hydrolyzed from abiraterone acetate (AA). The origin of CYP17A1 up-regulation under AA treatment was investigated in CRPC cell models by qRT-PCR and western-blot procedures. AA treatments of AR positive CRPC cell models led to decreased expression of androgen regulated genes such as PSA. In these cells diminished expression of androgen regulated genes was accompanied by an up-regulation of CYP17A1 expression within short-term treatments. No such effects became evident in AR-negative PC-3 cells. AR directed siRNA (siAR) used in VCaP cells significantly reduced mRNA expression and AR protein abundance. Such interference with AR signalling in the absence of abiraterone acetate also caused a marked up-regulation of CYP17A1 expression. Down-regulation of androgen regulated genes occurs in spite of an elevated expression of CYP17A1, the very target enzyme for this drug. CYP17A1 up-regulation already takes place within such short treatments with AA and does not require adaptation events over several cell cycles. CYP17A1 is also up-regulated in the absence of AA when AR signalling is physically eliminated by siAR. These results reveal an immediate counter-regulation of CYP17A1 expression whenever AR-signalling is inhibited adequately but not a persisting adaptation yielding drug resistance."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft (DFG)"],["dc.identifier.doi","10.1186/2193-1801-3-574"],["dc.identifier.isi","000359105300002"],["dc.identifier.pmid","25332874"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11151"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32049"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","2193-1801"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","66"],["dc.bibliographiccitation.journal","EJNMMI Research"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:48:52Z"],["dc.date.available","2018-11-07T09:48:52Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Prostate-specific membrane antigen (PSMA) is a promising target for diagnostics and therapy of prostate carcinoma (PCa). Based on the hypothesis that PSMA expression can be modulated by variations in androgen deprivation therapy (ADT), we investigated the binding of a PSMA-directed radiopharmaceutical in vitro in order to get an insight of the interactions between altered premedication and PSMA expression before repetitive PSMA-directed PET/CT for therapy response and targeted therapy implementation. Methods: The human castration-resistant PCa cell line VCaP (CRPC) was treated with either 1 nmol/L testosterone (T) over 20 passages yielding the androgen-sensitive cell line (revCRPC) or with 5 mu mol/L abiraterone acetate (AA) generating the abiraterone-tolerant subtype CRPCAA. In these cell lines, T and AA were varied by either supply or withdrawal of T and AA. PSMA expression of the three cell culture models was detected by Western blot and immunohistochemical staining. For quantitative measurement of tracer uptake, 0.3 nmol/L Ga-68-labelled PSMA-HBED-CC peptide (100-300 kBq/ml) was added to different treated parallel cultures (n = 9 each). Time-dependent uptake per 10(6) cells of each culture was calculated and evaluated. PSMA mRNA expression was investigated by qPCR. Results: PSMA expression increased dependently on intensified ADT in all three basic cell lines. Ga-68-PSMA-HBED-CC uptake almost doubled during 3 h in all cell lines (p < 0.01). Compared to the basic cells, pre-incubation with abiraterone for 48 h resulted in a significant increased uptake in CRPC (p < 0.001). In revCRPC, 48-h AA pre-incubation resulted in an eightfold higher uptake after 3 h (p < 0.001). Additional withdrawal of external testosterone increased the uptake up to tenfold (p < 0.01). The increase of PSMA expression upon ADT and AA treatments was confirmed by qPCR and Western blot data. Furthermore, in CRPCAA, 48-h AA withdrawal increased the uptake up to fivefold (p < 0.01). Conclusions: The investigated three PCa cell culture subtypes represent a serial preclinical model of androgen deprivation therapy as a proxy for clinical situations with differing basal PSMA expression. The uptake of PSMA-binding tracers could be stimulated by therapeutic effective short-term variation in premedication in all stages of ADT response. These complex interactions have to be considered in the interpretation of diagnostic imaging using PSMA ligands as well as in the optimal timing of PSMA-based therapies."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft DFG [TH 389/3-1, BR4700/1-1]"],["dc.identifier.doi","10.1186/s13550-015-0145-8"],["dc.identifier.isi","000364963600001"],["dc.identifier.pmid","26576996"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12584"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35393"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","2191-219X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","122"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","The Open Public Health Journal"],["dc.bibliographiccitation.lastpage","133"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.date.accessioned","2019-07-09T11:45:23Z"],["dc.date.available","2019-07-09T11:45:23Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose: To summarize the current evidence on preventive services utilization in cancer survivors. Methods: A systematic literature review and meta-analysis was conducted in February 2016. Studies were included if they compared the utilization of influenza vaccination, cholesterol/lipid testing, bone densitometry, or blood pressure measurement among survivors of adulthood cancer to cancer-free controls. Random effects meta-analyses were conducted to pool estimates. Results: Literature search identified 3740 studies of which 10 fulfilled the inclusion criteria. Cancer survivors were significantly more likely to utilize bone densitometry (OR=1.226, 95% CI: 1.114 – 1.350, p<0.001) and influenza vaccination (OR=1.565, 95% CI: 1.176 – 2.082, p=0.002) than cancer-free controls. No statistically significant differences were detected for blood pressure measurement and cholesterol/lipid testing (OR=1.322, 95% CI: 0.812 – 2.151, p=0.261; OR=1.046, 95% CI: 0.96 – 1.139, p=0.304). Conclusions: Cancer survivors were more likely to receive influenza vaccinations and bone densitometry. Future studies should evaluate underlying mechanisms and whether the utilization of preventive services translates into prolonged survival of cancer survivors. Implications for Cancer Survivors: Our meta-analysis demonstrated cancer survivors to be more likely to receive the preventive services such as influenza vaccination and bone densitometry than cancer free controls. Still, these results should be interpreted in the context of suboptimal utilization of preventive services in general, and for cancer survivors in specific. Future research should evaluate the underlying mechanisms and whether utilization of preventive services is associated with overall survival in cancer survivors."],["dc.identifier.doi","10.2174/1874944501811010122"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15190"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59219"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1874-9445"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Preventive Services Utilization Among Cancer Survivors Compared to Cancer-free Controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Health and Quality of Life Outcomes"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Buergy, Daniel"],["dc.contributor.author","Schneiberg, Vincent"],["dc.contributor.author","Schaefer, Joerg"],["dc.contributor.author","Welzel, Grit"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Wenz, Frederik"],["dc.date.accessioned","2020-12-10T18:38:59Z"],["dc.date.available","2020-12-10T18:38:59Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1186/s12955-018-0844-8"],["dc.identifier.eissn","1477-7525"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15494"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77503"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/15145 but duplicate"],["dc.rights","CC BY 4.0"],["dc.rights.holder","The Author(s)."],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Quality of life after low-dose rate-brachytherapy for prostate carcinoma – long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","64"],["dc.bibliographiccitation.journal","Urology Case Reports"],["dc.bibliographiccitation.lastpage","66"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Behnes, Carl Ludwig"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Leitsmann, Conrad"],["dc.date.accessioned","2019-07-09T11:45:15Z"],["dc.date.available","2019-07-09T11:45:15Z"],["dc.date.issued","2018"],["dc.description.abstract","Primary Bladder Adenocarcinoma is a rare malignancy that has been observed in a heterogeneous pa- tient population. This case report presents a 51 year old female with muscle-invasive primary bladder adenocarcinoma diagnosed in 2008. After transurethral resection and cystectomy with ileum neobladder adjuvant radi- ochemotherapy was administered. Two years later, a symptomatic fistula between neobladder and ileoileal anastomosis was excised, resulting in urinary incontinency. In 2016, the patient shows no signs of disease relapse but suffers from reduction of bladder capacity. This case report presents classical symptoms of adenocarcinoma of the bladder and a possible treat- ment regimen with associated side effects."],["dc.identifier.doi","10.1016/j.eucr.2018.02.006"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15073"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59191"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","2214-4420"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Primary bladder adenocarcinoma: Case report with long-term follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Surgery"],["dc.bibliographiccitation.volume","9"],["dc.contributor.affiliation","Reichert, Mathias; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Ploeger, Hannah Maria; 2Department of Pediatrics, University Hospital Bonn, Bonn, Germany"],["dc.contributor.affiliation","Uhlig, Annemarie; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Strauss, Arne; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Henniges, Philipp; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Trojan, Lutz; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.affiliation","Mohr, Mirjam Naomi; 1Department of Urology, University Medical Center Goettingen, Goettingen, Germany"],["dc.contributor.author","Reichert, Mathias"],["dc.contributor.author","Ploeger, Hannah Maria"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Henniges, Philipp"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Mohr, Mirjam Naomi"],["dc.date.accessioned","2022-12-07T08:25:13Z"],["dc.date.available","2022-12-07T08:25:13Z"],["dc.date.issued","2022-11-23"],["dc.date.updated","2022-12-07T06:37:25Z"],["dc.description.abstract","Purpose\r\nTo evaluate long-term continence rates (12 months) in patients after robot-assisted laparoscopic prostatectomy (RALP) in relation to their cognitive ability (CoAb), which proved to be a predictor for early post-prostatectomy incontinence.\r\n\r\nMaterial & Methods\r\nThis is the 12-month follow-up evaluation of our previously published observational single-center, prospective evaluation of 84 patients who underwent RALP as treatment of their localized prostate cancer between 07/2020 and 03/2021. Post-prostatectomy incontinence (PPI) was measured by asking patients about their 24 h pad usage, whereby 0 pads were considered continent and ≥1 pad was considered incontinent. CoAb was evaluated by performing the Mini-Mental State Examination prior to surgery. Possible predictors for PPI were evaluated using univariate and multivariable logistic regression models.\r\n\r\nResults\r\nMultivariable logistic regression analyses identified early incontinence status and nerve sparing (NS) as independent predictors for PPI after 12 months, resulting in a 5.69 times higher risk for PPI when the loss of urine was between 10 and 50 ml during the early performed pad test (one day after catheter removal) compared to 0–1 ml loss of urine [95% confidence interval (CI): 1.33–28.30, p = 0.024] and a 6.77 times higher risk for PPI, respectively, when only unilateral NS was performed compared to bilateral NS (95% CI: 1.79–30.89, p = 0.007). CoAb lost its predictive value for long-term PPI (p = 0.44).\r\n\r\nConclusion\r\nThe results of this study suggest that PPI is a dynamic, rather than a static condition with a dynamically changing pathophysiology within the first 12 months after RALP. Coping methods and therapies should adapt to this circumstance."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fsurg.2022.1055880"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118457"],["dc.language.iso","en"],["dc.relation.eissn","2296-875X"],["dc.rights","CC BY 4.0"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Understanding long-term continence rates after robot-assisted laparoscopic prostatectomy – one-year follow-up on “Cognitive ability as a non-modifiable risk factor for post-prostatectomy urinary incontinence”"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","26"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Kübler, Hubert"],["dc.contributor.author","Scheel, Birgit"],["dc.contributor.author","Gnad-Vogt, Ulrike"],["dc.contributor.author","Miller, Kurt"],["dc.contributor.author","Schultze-Seemann, Wolfgang"],["dc.contributor.author","vom Dorp, Frank"],["dc.contributor.author","Parmiani, Giorgio"],["dc.contributor.author","Hampel, Christian"],["dc.contributor.author","Wedel, Steffen"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Jocham, Dieter"],["dc.contributor.author","Maurer, Tobias"],["dc.contributor.author","Rippin, Gerd"],["dc.contributor.author","Fotin-Mleczek, Mariola"],["dc.contributor.author","von der Mülbe, Florian"],["dc.contributor.author","Probst, Jochen"],["dc.contributor.author","Hoerr, Ingmar"],["dc.contributor.author","Kallen, Karl-Josef"],["dc.contributor.author","Lander, Thomas"],["dc.contributor.author","Stenzl, Arnulf"],["dc.date.accessioned","2019-07-09T11:41:46Z"],["dc.date.available","2019-07-09T11:41:46Z"],["dc.date.issued","2015"],["dc.description.abstract","Background CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients with advanced castration-resistant prostate-cancer. Methods 44 Patients received up to 5 intra-dermal vaccinations. Three dose levels of total mRNA were tested in Phase I in cohorts of 3–6 patients to determine a recommended dose. In phase II, 32 additional patients were treated at the recommended dose. The primary endpoint was safety and tolerability, the secondary endpoint was induction of antigen specific immune responses monitored at baseline and at weeks 5, 9 and 17. Results The most frequent adverse events were grade 1/2 injection site erythema, injection site reactions, fatigue, pyrexia, chills and influenza-like illness. Possibly treatment related urinary retention occurred in 3 patients. The recommended dose was 1280 μg. A total of 26/33 evaluable patients treated at 1280 μg developed an immune response, directed against multiple antigens in 15 out of 33 patients. One patient showed a confirmed PSA response. In the subgroup of 36 metastatic patients, the Kaplan-Meier estimate of median overall survival was 31.4 months [95 % CI: 21.2; n.a]. Conclusions The self-adjuvanted RNActive® vaccine CV9103 was well tolerated and immunogenic. The technology is a versatile, fast and cost-effective platform allowing for creation of vaccines. The follow-up vaccine CV9104 including the additional antigens prostatic acid phosphatase (PAP) and Muc1 is currently being tested in a randomized phase IIb trial to assess the clinical benefit induced by this new vaccination approach. Trial registration EU Clinical Trials Register: EudraCT number 2008-003967-37 , registered 27 Jan 2009."],["dc.identifier.doi","10.1186/s40425-015-0068-y"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12365"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58508"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Surgery"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2021-04-14T08:27:57Z"],["dc.date.available","2021-04-14T08:27:57Z"],["dc.date.issued","2021"],["dc.description.abstract","Purpose: Several studies have demonstrated an advantage of 68Ga-PSMA-PET/CT as staging modality for detection of prostate cancer (PCa) metastases. Data concerning metastatic manifestation and impact on PCa development of mesorectal lymph nodes (MLN) is limited. Our investigation describes MLN metastases as index lesion in 68Ga-PSMA PET/CT imaging for recurrent PCa. Methods: Twelve PCa patients with biochemical recurrence (BCR) after primary therapy who prospectively underwent a baseline 68Ga-PSMA-PET/CT initially showed MLN metastases. Eight of these patients received a follow-up 68Ga-PSMA-PET/CT to evaluate treatment response and further evolution. Prostate-specific antigen (PSA)-levels, changes in PSMA-uptake of MLN metastases and further 68Ga-PSMA PET/CT findings were recorded. Results: Median PSA at the first 68Ga-PSMA-PET/CT was 5.39 ng/ml. In all patients therapeutic management changed after the first 68Ga-PSMA-PET/CT. Androgen deprivation therapy (ADT) was initiated in seven of eight patients, one patient restarted initial ADT. Three patients additionally received salvage radiation therapy (sRT) including the prostatic lodge and docetaxel chemotherapy was started in one case. At follow-up, a decrease of PSA-level was detected in all patients (median 2.05 ng/ml) after median 10 months. In six of eight patients we observed a decrease or complete regress of PSMA-uptake in MLN in the follow-up 68Ga-PSMA-PET/CT. Conclusion: MLN metastases detected by 68Ga-PSMA-PET/CT seem to be a relevant localization of tumor manifestation and may serve as index lesion in the treatment of recurrent PCa. Besides the known oncological benefits of ADT and sRT, in case of sole MLN metastases individualized therapy like salvage lymphadenectomy or RT with a defined radiation field could be options for these patients."],["dc.identifier.doi","10.3389/fsurg.2021.637134"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82459"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","2296-875X"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Mesorectal Lymph Node Metastases as Index Lesion in 68Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","201"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Urologia Internationalis"],["dc.bibliographiccitation.lastpage","206"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Martinschek, Andreas"],["dc.contributor.author","Stumm, Lisa"],["dc.contributor.author","Ritter, Manuel"],["dc.contributor.author","Heinrich, Elmar"],["dc.contributor.author","Bolenz, Christian"],["dc.contributor.author","Trojan, Lutz"],["dc.date.accessioned","2020-12-10T18:37:48Z"],["dc.date.available","2020-12-10T18:37:48Z"],["dc.date.issued","2017"],["dc.description.abstract","Objectives: To evaluate in a prospective, controlled, nonrandomized study the surgical stress and acute-phase systemic response in robotic-assisted laparoscopic prostatectomy (RALP) compared to open radical retro-pubic prostatectomy (ORRP) by measuring humoral mediators. Methods: Forty consecutive patients undergoing either RALP or ORRP were prospectively included to assess the extent of systemic response. Blood samples were collected before surgery (T1), at the time of prostatectomy (T2), at the time of wound closure (T3), and 12 h (T4), 24 h (T5), and 48 h (T6) after surgery, and assayed for interleukins (IL-6 and IL-10), C-reactive protein (CRP), and hemoglobin. A 2-sided p \\u0026lt; 0.05 was considered to indicate significance. Results: Baseline levels of IL-6, IL-10, and CRP were comparable in both arms of the study. IL-6 and IL-10 increased in both groups during surgery and reached maximum levels at 12 and 24 h after surgery. The RALP and RRP groups differed significantly at T2 (p = 0.009), T3 (p = 0.046), T5 (p = 0.05) and T6 (p = 0.0007) for IL-6, and at T3 (p = 0.05) and T4 (p = 0.05) for IL-10. CRP levels differed significantly at 48 h postoperative (p = 0.0053). The maximum levels of all 3 mediators in the RALP group were significantly lower than those in the open surgery group. Patients in the RALP group experienced less pain from day 2 to 4 according to the Visual Analog Scale (p \\u0026lt; 0.05). Conclusions: The study suggests that IL-6 and IL-10 are useful objective markers for surgical stress and that tissue trauma and activation of post-aggression metabolism seem to be less in RALP compared to ORRP."],["dc.identifier.doi","10.1159/000478027"],["dc.identifier.eissn","1423-0399"],["dc.identifier.issn","0042-1138"],["dc.identifier.pmid","28768259"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77099"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1423-0399"],["dc.relation.issn","0042-1138"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Prospective, Controlled Study of Invasiveness and Post-Aggression Metabolism in Patients Undergoing Robotic-Assisted Radical Prostatectomy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]